Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 10, 2025
The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trialKara M Ruicci, Aisling Barry, Xiang Y Ye, et al.
International Journal of Radiation Oncology, Biology, Physics|November 6, 2021
Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526)Juanita Crook, Joseph P Rodgers, Thomas M Pisansky, et al.
JAMA Network Open|February 25, 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate CancerCristian Udovicich, Patrick Cheung, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|August 28, 2022
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate CancerRachel M Glicksman, Matthew Ramotar, Ur Metser, et al.
International Journal of Radiation Oncology, Biology, Physics|November 25, 2025
Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical TrialRachel M Glicksman, Jeff Winter, Andrew McPartlin, et al.
Clinical and Translational Radiation Oncology|April 21, 2026
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trialKara M Ruicci, Joelle Helou, Aisling Barry, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapyYasir Alayed, Melanie Davidson, Harvey Quon, et al.
European Urology|March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis HypothesisRachel M Glicksman, Ur Metser, Douglass Vines, et al.
BMC Palliative Care|September 7, 2024
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocolDavid A Palma, Meredith E Giuliani, Rohann J M Correa, et al.
JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.
Pageof 7